Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
Publishing timestamp: 2024-01-28 12:10:59
Summary
The article discusses the patent cliffs that big pharmaceutical companies like Bristol Myers Squibb, Merck, and Johnson & Johnson are facing between now and 2030. These patent expirations open the door for competitors to sell copycat drugs at lower prices, putting billions of dollars in sales at risk. However, some companies are well-prepared to offset these losses through drug pipelines, acquisitions, and partnerships. The article also mentions the potential impact of Medicare drug price negotiations and the differences between small-molecule drugs and biologics in terms of patent cliffs. It concludes by discussing the strategies that these companies are employing to extend patent protections and delay competition.
Sentiment: MIXED
Tickers: AMGN, MRK, TEVA-IL, 4568.T-JP, TEVA, KRTX, JNJ, BMY, ABBV, MRNA, ALVO,
Keywords: patents, teva pharmaceutical industries ltd, amgen inc, moderna inc, pharmaceuticals, abbvie inc, merck & co inc, breaking news, alvotech sa, johnson & johnson, health care industry, daiichi sankyo co ltd, biotechnology, business, bristol-myers squibb co, biotech and pharmaceuticals, business news, karuna therapeutics inc,
Source: https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html